A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.

-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, March 23, 2013

Biogen’s Tecfidera multiple sclerosis drug wins EU agency backing

Published: March 22, 2013

By Meg Tirrell— Bloomberg News

Biogen Idec, maker of the multiple sclerosis drugs Avonex and Tysabri, won European Union backing for Tecfidera, its first pill for the central nervous system disease.

Biogen should be granted marketing authorization for the drug, the European Medicines Agency’s Committee for Medicinal Products for Human Use said in a statement Friday. The European Commission usually follows the committee’s advice.

The drug, formerly known as BG-12, will follow Novartis’s Gilenya to the market in the EU as an oral option for the treatment of MS. Because of its safety profile and efficacy, Weston, Mass.-based Biogen’s Tecfidera may generate $3.25 billion in annual revenue by 2017, based on the average analyst estimate compiled by Bloomberg.

Biogen employs more than 1,000 people at its Research Triangle Park campus.

Multiple sclerosis affects an estimated 2.1 million people worldwide, causing symptoms ranging from limb numbness to blindness and paralysis, according to the National Multiple Sclerosis Society. Other MS drugs, including Biogen’s, are given by injection or intravenous infusion, and patient anticipation for Tecfidera may drive it to capture as much as 20 percent of the MS market within a year, according to Eric Schmidt, a Cowen & Co. analyst.

“This will probably be the No. 1 drug in MS,” said Michael Yee, an analyst with RBC Capital Markets in San Francisco, in a telephone interview this week. He recommends buying Biogen shares.

Biogen’s stock has doubled since April 2011 when the company first reported positive data from a late-stage trial of Tecfidera. The results were better than analysts and investors had expected, and they were bolstered later that year with results from a second trial, dubbed Confirm.

The most common form of MS is relapsing-remitting, characterized by neurological attacks followed by periods of recovery. The studies together showed that Tecfidera reduced patients’ annual relapse rate by 49 percent when given either twice a day or three times a day, and cut the proportion of patients who relapsed by 43 percent at twice-daily dosing and 47 percent at three times daily compared with placebo.

Overall, side effects were similar across the placebo and treatment groups, with the most common adverse events associated with Tecfidera being flushing and gastrointestinal effects, the company said.

A decision on Tecfidera is due from the U.S. Food and Drug Administration by Thursday. The drug was delayed by the FDA in October for three months without asking for additional studies. The agency said it needed more time to review the application, Biogen said.

SYMPTOMS of MS

In multiple sclerosis , damage to the myelin in the central nervous system (CNS), and to the nerve fibers themselves, interferes with the transmission of nerve signals between the brain and spinal cord and other parts of the body. This disruption of nerve signals produces the primary symptoms of MS, which vary depending on where the damage has occurred.

Over the course of the disease, some symptoms will come and go, while others may be more lasting.

Autoimmune Research and Treatments

MS Coalition Associate Member

iConquerMS

partner link

Healing the Soul, by B. Khatri, MD

Click photo for more detail

Sharecare Marketing - March 2014 - LISTED Stuart among the Top "10"

Social HealthMakers: Multiple Sclerosis

Disclaimer:

"Stu's Views & MS News" / 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

2014 MS Symposium from Miami, Fl

Brian Steingo, MD - Presents on Dietary & Self Aspects

MS Views and News

MS Views and News (MSVN), is dedicated to the global collection and distribution of information concerning Multiple Sclerosis (MS). Through partnering relationships, MSVN provides education, advocacy and service to empower and enhance the quality of life of the MS community.

Marketing Opportunities with MS Views and News

Att: Marketers :

Get New Exposure to either venues in Florida, the USA or Globally

Becoming a Sponsor of MS Views and News will enable us a few dollars more to host Multiple Sclerosis learning programs for those affected by MS and a sponsorship at the correct tier would place your logo and url on our site(s) and possibly with our social media offering you lots of new exposure.

FL Dept of Agriculture

MS Views and News, Inc. is registered with the Florida Department of Agriculture and Consumer Services, Registration # CH37993

A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE (800-435-7352) WITHIN THE STATE. REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE.